Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection

New England Journal of Medicine

Volumn 367, Issue 3, 2012, Pages 224-232

  Esbjörnsson, Joakim ^a   Månsson, Fredrik ^f   Kvist, Anders ^b   Isberg, Per Erik ^c   Nowroozalizadeh, Salma ^g   Biague, Antonio J ^h   Da Silva, Zacarias J ^h   Jansson, Marianne ^d,g   Fenyö, Eva Maria ^d   Norrgren, Hans ^e   Medstrand, Patrik ^a,d  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY SCHOOL OF ECONOMICS AND MANAGEMENT   (Sweden)

^d LUND UNIVERSITY   (Sweden)

^e LUND UNIVERSITY   (Sweden)

^f LUND UNIVERSITY   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

^h National Public Health Laboratory   (Guinea-Bissau)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COHORT ANALYSIS; DISEASE COURSE; ENZYME INHIBITION; FEMALE; FOLLOW UP; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MOLECULAR EVOLUTION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

EID: 84863993899     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1113244     Document Type: Article

References (39)

1. Kanki PJ, Travers KU, Mboup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994;343:943-6. (Pubitemid 24117229)
2. Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994;265:1587-90. (Pubitemid 24308975)
3. De Cock KM, Adjorlolo G, Ekpini E, et al. Epidemiology and transmission of HIV-2: why there is no HIV-2 pandemic. JAMA 1993;270:2083-6. [Erratum, JAMA 1994;271:196.] (Pubitemid 23318173)
4. O'Donovan D, Ariyoshi K, Milligan P, et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. AIDS 2000;14:441-8. (Pubitemid 30182442)
5. Hamel DJ, Sankalé JL, Eisen G, et al. Twenty years of prospective molecular epidemiology in Senegal: changes in HIV diversity. AIDS Res Hum Retroviruses 2007;23:1189-96. (Pubitemid 350014768)
6. Månsson F, Biague A, da Silva ZJ, et al. Prevalence and incidence of HIV-1 and HIV-2 before, during and after a civil war in an occupational cohort in Guinea-Bissau, West Africa. AIDS 2009;23:1575-82.
7. Travers K, Mboup S, Marlink R, et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995;268:1612-5. [Erratum, Science 1995:268:1833.]
8. Norrgren H, Andersson S, Biague AJ, et al. Trends and interaction of HIV-1 and HIV-2 in Guinea-Bissau, West Africa: no protection of HIV-2 against HIV-1 infection. AIDS 1999;13:701-7. (Pubitemid 29286705)
9. Greenberg AE. Possible protective effect of HIV-2 against incident HIV-1 infection: review of available epidemiological and in vitro data. AIDS 2001;15:2319-21. (Pubitemid 34059841)
10. Al-Harthi L, Owais M, Arya SK. Molecular inhibition of HIV type 1 by HIV type 2: effectiveness in peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1998;14:59-64. (Pubitemid 28028617)
11. Arya SK, Gallo RC. Human immunodeficiency virus (HIV) type 2-mediated inhibition of HIV type 1: a new approach to gene therapy of HIV-infection. Proc Natl Acad Sci U S A 1996;93:4486-91. (Pubitemid 26144313)
12. Kokkotou EG, Sankale JL, Mani I, et al. In vitro correlates of HIV-2-mediated HIV-1 protection. Proc Natl Acad Sci U S A 2000;97:6797-802. (Pubitemid 30412794)
13. de Silva TI, van Tienen C, Rowland-Jones SL, Cotten M. Dual infection with HIV-1 and HIV-2: double trouble or destructive interference? HIV Ther 2010;4:305-23.
14. Andersson S, da Silva Z, Norrgren H, Dias F, Biberfeld G. Field evaluation of alternative testing strategies for diagnosis and differentiation of HIV-1 and HIV-2 infections in an HIV-1 and HIV-2-prevalent area. AIDS 1997;11:1815-22. (Pubitemid 27500957)
15. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992;41:1-19.
16. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization, 2007 (http://www.who.int/hiv/pub/guidelines/ HIVstaging150307.pdf).
17. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990;322:166-72. (Pubitemid 20036390)
18. Taylor JM, Fahey JL, Detels R, Giorgi JV. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr 1989;2:114-24. (Pubitemid 19127086)
19. Esbjörnsson J, Månsson F, Martínez-Arias W, et al. Frequent CXCR4 tropism of HIV-1 subtype A and CRF02-AG during late-stage disease - indication of an evolving epidemic in West Africa. Retrovirology 2010;7:23.
20. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996;17:343-6. (Pubitemid 26342716)
21. Wolinsky SM, Korber BT, Neumann AU, et al. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996;272:537-42. (Pubitemid 26138195)
22. Shankarappa R, Margolick JB, Gange SJ, et al. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 1999;73:10489-502.
23. Nowak MA, Anderson RM, McLean AR, Wolfs TF, Goudsmit J, May RM. Antigenic diversity thresholds and the development of AIDS. Science 1991;254:963-9. (Pubitemid 21917418)
24. Bello G, Casado C, Sandonis V, et al. Plasma viral load threshold for sustaining intrahost HIV type 1 evolution. AIDS Res Hum Retroviruses 2007;23:1242-50. (Pubitemid 350017603)
25. Troyer RM, Collins KR, Abraha A, et al. Changes in human immunodeficiency virus type 1 fitness and genetic diversity during disease progression. J Virol 2005;79:9006-18. (Pubitemid 40934811)
26. Lemey P, Kosakovsky Pond SL, Drummond AJ, et al. Synonymous substitution rates predict HIV disease progression as a result of underlying replication dynamics. PLOS Comput Biol 2007;3(2):e29.
27. Lee HY, Perelson AS, Park SC, Leitner T. Dynamic correlation between intrahost HIV-1 quasispecies evolution and disease progression. PLOS Comput Biol 2008;4(12):e1000240.
28. Otten RA, Adams DR, Kim CN, et al. Chronic HIV-2 infection protects against total CD4+ cell depletion and rapid disease progression induced by SHIV89.6p challenge. AIDS 2004;18:1127-35. (Pubitemid 38738512)
29. Putkonen P, Thorstensson R, Albert J, et al. Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection. AIDS 1990;4:783-9. (Pubitemid 20267174)
30. Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood 2004;104:942-7. (Pubitemid 39038012)
31. Giorgi JV, Lyles RH, Matud JL, et al. Predictive value of immunologic and virologic markers after long or short duration of HIV-1 infection. J Acquir Immune Defic Syndr 2002;29:346-55. (Pubitemid 34288887)
32. Cavaleiro R, Sousa AE, Loureiro A, Victorino RM. Marked immunosuppressive effects of the HIV-2 envelope protein in spite of the lower HIV-2 pathogenicity. AIDS 2000;14:2679-86. (Pubitemid 32118721)
33. Schindler M, Münch J, Kutsch O, et al. Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 2006;125:1055-67. (Pubitemid 43884762)
34. Akimoto H, Kaneko H, Sekigawa I, Hashimoto H, Kaneko Y, Yamamoto N. Binding of HIV-2 envelope glycoprotein to CD8 molecules and related chemokine production. Immunology 1998;95:214-8. (Pubitemid 28459384)
35. Zheng NN, Kiviat NB, Sow PS, et al. Comparison of human immunodeficiency virus (HIV)-specific T-cell responses in HIV-1- and HIV-2-infected individuals in Senegal. J Virol 2004;78:13934-42. (Pubitemid 39612790)
36. Zheng NN, McElrath MJ, Sow PS, et al. Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection. J Virol 2007;81:9061-71. (Pubitemid 47311449)
37. Weiss RA, Clapham PR, Weber JN, et al. HIV-2 antisera cross-neutralize HIV-1. AIDS 1988;2:95-100.
38. Ozkaya Sahin G, Holmgren B, da Silva Z, et al. Potent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1. J Virol 2012;86:961-71.
39. Markham RB, Wang WC, Weisstein AE, et al. Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline. Proc Natl Acad Sci U S A 1998;95:12568-73. (Pubitemid 28483805)